Search

Your search keyword '"Yao, Qiang"' showing total 7 results
Start Over Author "Yao, Qiang" Journal blood purification
7 results on '"Yao, Qiang"'

2. Hemofilter with Adsorptive Capacities: Case Report Series

Author

Zhang, Ling, primary, Yan Tang, Gloria Kai, additional, Liu, Songqiao, additional, Cai, Jing, additional, Chan, Wai Ming, additional, Yang, Yi, additional, Chang, Ping, additional, Wei, Tiantian, additional, Liu, Xinyu, additional, Yao, Qiang, additional, Wang, Minmin, additional, and Marshall, Mark R., additional

Published
2019
Full Text
View/download PDF

6. Peroxisome Proliferator-Activated Receptor-γ Agonists Diminish Peritoneal Functional and Morphological Changes Induced by Bioincompatible Peritoneal Dialysis Solution

Author

Yao, Qiang, primary, Pawlaczyk, Krzysztof, additional, Ayala, Ernesto Rodríguez, additional, Kuzlan, Malgorzata, additional, Styszynski, Arkadiusz, additional, Breborowicz, Andrzej, additional, Heimbürger, Olof, additional, Qian, Jiaqi, additional, Stenvinkel, Peter, additional, Axelsson, Jonas, additional, and Lindholm, Bengt, additional

Published
2006
Full Text
View/download PDF

7. Peroxisome proliferator-activated receptor-gamma agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution.

Author

Yao Q, Pawlaczyk K, Ayala ER, Kuzlan M, Styszynski A, Breborowicz A, Heimburger O, Qian J, Stenvinkel P, Axelsson J, and Lindholm B

Subjects
Animals, Hemodialysis Solutions pharmacology, Male, Peritoneum pathology, Rats, Rats, Wistar, Rosiglitazone, Signal Transduction drug effects, Smad Proteins metabolism, Transforming Growth Factors metabolism, Vascular Endothelial Growth Factor A metabolism, Hemodialysis Solutions adverse effects, Hypoglycemic Agents pharmacology, PPAR gamma antagonists & inhibitors, Peritoneal Dialysis adverse effects, Peritoneum metabolism, Thiazolidinediones pharmacology
Abstract

Background: To evaluate if peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists have a potential protective effect on the peritoneum changes induced by bioincompatible peritoneal dialysis (PD) solution in vivo., Methods: Male Wistar rats were dialyzed three times daily for 28 days with 1.36% Dianeal (two groups: with (D+R) or without (D) rosiglitazone) or 1.36% Physioneal (two groups: with (P+R) or without (P) rosiglitazone). Peritoneal transport of fluid and small solutes was assessed. Nine rats that did not receive dialysis served as controls., Results: Significant morphological changes were found in the D group compared with controls. Additional use of rosiglitazone in the D+R group resulted in less morphological changes and expression of collagen I as well as an increased drainage volume. The expression of VEGF was inhibited by rosiglitazone while no apparent effect was found regarding TGF/Smad pathway., Conclusions: The addition of rosiglitazone to standard dialysis fluids can maintain the peritoneal morphology and increase ultrafiltration in a PD rat model.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results